GILD vs NVS
Gilead Sciences and Novartis AG, both Healthcare
Novartis AG is the larger company at $275B against $187B. Over the past year GILD returned +34% against +20% for NVS. The RyuScore puts NVS ahead, 75 against 44 out of 100.
| Figure | GILD | NVS |
|---|---|---|
| Last close | $150 | $144 |
| Market cap | $187B | $275B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 21.3 |
| Dividend yield | 2.1% | n/a |
| 1-year return | +34% | +20% |
| 5-year return | +154% | +104% |
| RyuScoresector-relative, 1–10 | 44/100 | 75/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Gilead Sciences
Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.